These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

683 related items for PubMed ID: 29857784

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
    Shah S, Blanchette CM, Coyle JC, Kowalkowski M, Arthur ST, Howden R.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
    [Abstract] [Full Text] [Related]

  • 3. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M.
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [Abstract] [Full Text] [Related]

  • 4. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
    Moll K, Sun SX, Ellis JJ, Howe A, Amin A.
    Int J Chron Obstruct Pulmon Dis; 2015 Mar; 10():565-76. PubMed ID: 25834417
    [Abstract] [Full Text] [Related]

  • 5. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C, Lim J, Golembesky A, Shrestha S, Wang L, Griebsch I.
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [Abstract] [Full Text] [Related]

  • 6. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW, Mortell KE, Hippe DS, Brunner MC.
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [Abstract] [Full Text] [Related]

  • 7. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
    Trantham L, Sikirica MV, Candrilli SD, Benson VS, Mohan D, Neil D, Joshi AV.
    J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
    [Abstract] [Full Text] [Related]

  • 8. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD.
    Appl Health Econ Health Policy; 2009 Apr; 7(1):31-41. PubMed ID: 19558193
    [Abstract] [Full Text] [Related]

  • 9. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [Abstract] [Full Text] [Related]

  • 10. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, Lipscomb J, Knopf KB, Buesching DP.
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [Abstract] [Full Text] [Related]

  • 11. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL, Simon MS, Bylsma LC, Ruterbusch JJ, Beebe-Dimmer JL, Schultz NM, Flanders SC, Barlev A, Fryzek JP, Quek RGW.
    Cancer; 2018 May 15; 124(10):2104-2114. PubMed ID: 29505670
    [Abstract] [Full Text] [Related]

  • 12. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA, Arunachalam A, Li H, Camacho R, He J, Zhong Y, Lubiniecki GM, Carbone DP.
    Clin Lung Cancer; 2018 Sep 15; 19(5):e629-e645. PubMed ID: 29885945
    [Abstract] [Full Text] [Related]

  • 13. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
    Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S.
    Int J Chron Obstruct Pulmon Dis; 2017 Sep 15; 12():735-744. PubMed ID: 28260880
    [Abstract] [Full Text] [Related]

  • 14. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL, Goyal RK, Able SL, Brown J, Li L, Kaye JA.
    Lung Cancer; 2015 Feb 15; 87(2):176-85. PubMed ID: 25532680
    [Abstract] [Full Text] [Related]

  • 15. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia.
    Lee TY, Johnson A, Cooke CE, Yared JA, Summers A, Yang K, Liu S, Tang B, Onukwugha E.
    J Manag Care Spec Pharm; 2024 May 15; 30(5):430-440. PubMed ID: 38701030
    [Abstract] [Full Text] [Related]

  • 16. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X, Marvel J, Yu TC, Wertz D, Geremakis C, Wang L, Stephenson JJ, Mannino DM.
    Int J Chron Obstruct Pulmon Dis; 2016 May 15; 11():1689-703. PubMed ID: 27555759
    [Abstract] [Full Text] [Related]

  • 17. Hospital Variation in Spending for Lung Cancer Resection in Medicare Beneficiaries.
    Jean RA, Bongiovanni T, Soulos PR, Chiu AS, Herrin J, Kim N, Xu X, Kim AW, Gross CP.
    Ann Thorac Surg; 2019 Dec 15; 108(6):1710-1716. PubMed ID: 31400321
    [Abstract] [Full Text] [Related]

  • 18. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
    Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ.
    J Med Econ; 2015 Apr 15; 18(4):312-22. PubMed ID: 25565443
    [Abstract] [Full Text] [Related]

  • 19. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
    Vyas A, Madhavan SS, Sambamoorthi U, Pan XL, Regier M, Hazard H, Kalidindi S.
    J Natl Compr Canc Netw; 2017 Nov 15; 15(11):1401-1409. PubMed ID: 29118232
    [Abstract] [Full Text] [Related]

  • 20. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A, Shafrin J, Zhao L, Green S, Curtice T, Marshall A, Paul D.
    J Med Econ; 2019 Apr 15; 22(4):350-358. PubMed ID: 30653389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.